Publicaciones en colaboración con investigadores/as de Princess Margaret Cancer Centre (13)

2023

  1. Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1590-1599

2022

  1. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284

2021

  1. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003

  2. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  3. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    Blood Cancer Journal, Vol. 11, Núm. 6

  4. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

2020

  1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221

2019

  1. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

    British Journal of Haematology

2018

  1. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    Haematologica, Vol. 103, Núm. 9, pp. 1518-1526

2017

  1. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905

2016

  1. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma

    New England Journal of Medicine, Vol. 375, Núm. 14, pp. 1319-1331

2015

  1. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152

  2. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631